Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality

Abstract

Objectives: Deep vein thrombosis (DVT) is a major health-care burden in Europe, but exact estimates are lacking. This study reports results from the PREFER venous thromboembolism (VTE) study concerning health-related quality of life (HrQoL) and mortality of patients with DVT. Methods: PREFER VTE was a prospective, observational study, conducted in 7 European countries, designed to provide data concerning treatment patterns, resource utilization, mortality, and QoL. First-time or recurrent patients with DVT were followed at 1, 3, 6, and 12 months. Health-related QoL—as measured by the EuroQoL 5-Dimension 5-Level instrument ( EQ-5D-5L)—was analyzed using Tobit regression with repeated measures, assessing the impact of baseline characteristics stratified by cancer activity. Mortality was analyzed using logistic regression. Results: At baseline, patients with DVT had a 0.14 lower EQ-5D-5L index score (0.72 for total sample) compared to the reference UK population (0.85). The EQ-5D-5L index score improved from baseline to 12 months in patients with active cancer (from 0.70 to 0.79) and those without (0.72-0.87); 7.3% died within a year, a 5.2% excess mortality compared to the age- and gender-adfjusted general population. The 12-month mortality rate of DVT varied between 2.9% in the pooled data from Germany, Switzerland, or Austria and 15.4% in Italy. Furthermore, the mortality rate differed between patients with active cancer and those without (42.9% vs 4.7%). Conclusions: Deep vein thrombosis is associated with a substantial burden of illness in terms of HrQoL at baseline, which following treatment normalizes after 12 months and has a significant mortality rate. In addition, active cancer has a significant impact on mortality and the HrQoL of patients with DVT.

Cardiovascular Mortality after Venous Thromboembolism: A Meta-Analysis of Prospective Cohort Studies

“…5,10,[12][13][14]23,28,29 The pooled frequency of recurrent VTE-related deaths among all causes of deaths was 7.9% (eight studies, 805 deaths, 95% CI: 3.9-13.1; I 2 ¼ 72.9%, p-Egger: 0.84). 5,10,[12][13][14]23,28,29 Two studies reported frequency of cardiovascular death in patients with VTE and in controls without VTE. 11,26 The pooled frequency of cardiovascular death in controls was 0.3% (two studies, 48,946 patients, 95% CI: 0.03-0.95;…”

Deep-vein thrombosis in Europe — Burden of illness in relationship to healthcare resource utilization and return to work

“…The most commonly reported DVT symptoms included pain and swelling, with over 72% and 54%, respectively, across all countries. The baseline characteristics of the total sample and cancer subgroup can be found elsewhere [9].…”

“…Specific attention is given to the differences per country, the difference between patients with active cancer and those without and the association between the burden of the disease and baseline patient characteristics. A separate paper concerning mortality and health related quality of life of patients with DVT is available elsewhere [9].…”

Preventing Venous Thromboembolism after elective total hip arthroplasty surgery – are the current guidelines appropriate? Venous thromboembolism prophylaxis in elective total hip arthroplasty surgery

“…Elective Total Hip Arthroplasty (THA) surgery has proven to be a reliable and effective surgical procedure, with widely reported satisfactory clinical outcomes . Venous Thromboembolism (VTE), encompassing Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), presents a substantial burden of disease, both in terms of health-related quality of life and long-term mortality 1 . VTE is a result of peripheral vein thrombosis (DVT), leading to embolisation and thrombosis of a segmental branch of the pulmonary artery (PE) 2 .…”